Skip to content
Screener

PP&E (Net) at other companies

Becton, Dickinson and Company logo
Becton, Dickinson and CompanyBDX
$6.08B-10.8%
Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
$10.76B+11.6%
Danaher logo
DanaherDHR
$5.83B+9.7%
Revvity logo
RevvityRVTY
$456.25M-8.6%
Agilent Technologies logo
Agilent TechnologiesA
$2.1B+9.8%
Fulgent Genetics, Inc. logo
Fulgent Genetics, Inc.FLGT
$116.34M+8.7%

Segments

By geography

See full
APAC$9.58M+0.7%
EMEA$412K-12.5%

Other financials

Income statement

See full
Revenue$48.1M+5.6%
Gross profit$28.3M+18.7%
Operating income-$11.4M-7.3%
Net income-$12.2M-118%
EPS (diluted)-$0.09-125%

Balance sheet

See full
Cash & equivalents$73.8M-2.2%
Total debt$17.0M-6.6%
Total equity$322.0M-14.7%
Total assets$446.9M-9.4%

Cash flow

See full
Operating cash flow-$2.7M-2,089%
CapEx$2.2M+40.5%
Free cash flow-$849.0K+42.2%

Valuation

See full
Market cap$605.72M+25.6%
Enterprise value$548.91M+29.2%
P/S2.9×+0.5×

Profitability

See full
Gross margin53.2%-1.2pp
Operating margin-21.6%
Net margin-39%
FCF margin-5.8%-11.4pp

Returns & leverage

See full
Return on equity-23%
Debt / equity0.1×0.0×
Current ratio4.5×-0.7×

Where this comes from

Reported directly by Cytek Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.

The source filing: Cytek Biosciences, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 5:06 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-053496
(In thousands, except share and per share data)June 30,2026December 31,2025
Inventories52,25148,428
Prepaid expenses and other current assets13,97819,530
Total current assets377,931391,996
Property and equipment, net20,80118,009
Operating lease right-of-use assets10,96211,315
Goodwill16,69016,697
Intangible assets, net14,86516,821
Other noncurrent assets5,6856,704

Item 1. Consolidated Financial Statements (Unaudited)

FAQ

What is Cytek Biosciences, Inc.'s PP&E (net)?
Cytek Biosciences, Inc. (CTKB) reported PP&E (net) of $20.8M in Q2 2026.
How has Cytek Biosciences, Inc.'s PP&E (net) changed year-over-year?
Cytek Biosciences, Inc.'s PP&E (net) increased by 13.3% year-over-year, from $18.35M to $20.8M.
What is the long-term trend for Cytek Biosciences, Inc.'s PP&E (net)?
Over 5 years (2020 to 2025), Cytek Biosciences, Inc.'s PP&E (net) has grown at a 53.1% compound annual growth rate (CAGR), from $2.14M to $18.01M.
What does PP&E (net) mean?
Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.

Ask your AI about Cytek Biosciences, Inc.'s pp&e (net).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude